Malta - engelsk - Medicines Authority

labomed ltd delf building,sliema road, gzira gzr1637, malta - hepatitis b, surface antigen, rdna - suspension for injection - hepatitis b surface antigen (rdna) 10 µg/5ml - vaccines

Malta - engelsk - Medicines Authority

medical logistics ltd no 8, ivo muscat azzopardi street, st julians stj 1905, malta - hepatitis b, surface antigen, rdna - suspension for injection in pre-filled syringe - hepatitis b surface antigen (rdna) 20 microgram(s) - vaccines

Malta - engelsk - Medicines Authority

medical logistics ltd no 8, ivo muscat azzopardi street, st julians stj 1905, malta - hepatitis b, surface antigen, rdna - suspension for injection in pre-filled syringe - hepatitis b surface antigen (rdna) 10 microgram(s) - vaccines

Malta - engelsk - Medicines Authority

nm pharma limited 3/4, cantrija complex triq it-targa, il-maghtab naxxar nxr 6613 , malta - hepatitis b, surface antigen, rdna - suspension for injection in pre-filled syringe - hepatitis b surface antigen (rdna) 20 µg - vaccines

Malta - engelsk - Medicines Authority

nm pharma limited 3/4, cantrija complex triq it-targa, il-maghtab naxxar nxr 6613 , malta - hepatitis b, surface antigen, rdna - suspension for injection in pre-filled syringe - hepatitis b surface antigen (rdna) 10 µg - vaccines

Den europeiske union - slovensk - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - površinski antigen hepatitisa b - hepatitis b; immunization - cepiva - fendrix je indicirano pri mladostnikih in odraslih v starosti od 15 let naprej, za aktivne imunizacije proti okužbe z virusom hepatitisa b (hbv) posledica vse znane podtipov za bolnike z ledvičnim (vključno s pre-hemodializni in hemodializnega bolniki).

Den europeiske union - nederlandsk - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - hepatitis b-oppervlakte-antigeen - hepatitis b; immunization - vaccins - fendrix is geïndiceerd bij adolescenten en volwassenen vanaf de leeftijd van 15 jaar voor actieve immunisatie tegen hepatitis b-virusinfectie (hbv) veroorzaakt door alle bekende subtypen voor patiënten met nierinsufficiëntie (inclusief pre-hemodialyse en hemodialyse patiënten).

Den europeiske union - dansk - EMA (European Medicines Agency)

mcm vaccine b.v. - difteri toxoid, tetanus toxoid, bordetella pertussis antigener: kighoste toxoid, trådformede hæmagglutinin, pertactin, fimbriae typer 2 og 3, hepatitis b surface antigen, der er produceret i gær celler, poliovirus (inaktiveret): type 1 (mahoney), type 2 (mef-1), type 3 (saukett), produceret i vero celler/ haemophilus influenzae type b polysakkarid (polyribosylribitol fosfat), der er konjugeret til meningokok-protein. - meningitis, haemophilus; poliomyelitis; tetanus; diphtheria; whooping cough; hepatitis b - vacciner - vaxelis (dtap-hb-ipv-hib) er indiceret til primære og booster vaccination hos spædbørn og småbørn i alderen fra 6 uger, mod difteri, stivkrampe, kighoste, hepatitis b, polio og invasive sygdomme forårsaget af haemophilus influenzae type b (hib). brug af vaxelis bør være i overensstemmelse med officielle anbefalinger.

Den europeiske union - dansk - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - hepatitis a-virus (inaktiveret), hepatitis b overflade antigen - hepatitis b; hepatitis a; immunization - vacciner - twinrix adult er indiceret til brug hos ikke-immune voksne og unge 16 år og derover, der er i fare for både hepatitis a og hepatitis b infektion.

Den europeiske union - engelsk - EMA (European Medicines Agency)

mcm vaccine b.v. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens: pertussis toxoid, filamentous haemagglutinin, pertactin, fimbriae types 2 and 3, hepatitis b surface antigen produced in yeast cells, poliovirus (inactivated): type 1 (mahoney), type 2 (mef-1), type 3 (saukett) produced in vero cells/ haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to meningococcal protein. - meningitis, haemophilus; poliomyelitis; tetanus; diphtheria; whooping cough; hepatitis b - vaccines - vaxelis (dtap-hb-ipv-hib) is indicated for primary and booster vaccination in infants and toddlers from the age of 6 weeks, against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and invasive diseases caused by haemophilus influenzae type b (hib). the use of vaxelis should be in accordance with official recommendations.